CNTG News and Press, Centogene N.V. From 04/28/23

2023-04-28 10:03:38 ET Gainers: Tempest Therapeutics ( TPST ) +72% . CVRx ( CVRX ) +25% . ImmunoGen ( IMGN ) +22% . Apyx Medical ( APYX ) +17% . bluebird bio ( BLUE ) +17% . Losers: Hillstream BioPharma ( HILS ) -56%...

2023-04-28 08:33:44 ET Hillstream BioPharma ( HILS ) -57% on pricing $2.65M equity offering . Centogene ( CNTG ) -26% receives Nasdaq non-compliance notice . Cloudflare ( NET ) -25% after Q1 earnings release . Snap ( SNAP ) -18% afte...

Enabling Rapid and Reliable Diagnosis and Research of Rare Genetic Diseases Around the World CENTOGENE’s FilterTool aims to fuel rapid, reliable analysis for diagnosis and research of rare genetic diseases by significantly reducing time- and resource-intensive processes – en...

2023-04-25 11:28:44 ET Numerous factors in the current stock market must be considered as you search for penny stocks to invest in. Emotions are running high between the broad economic concerns of recession and inflation or the potential for a stock market crash in 2023. This heightened...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for April 2023. CENTOGENE representatives...

2023-04-12 07:02:01 ET Centogene ( NASDAQ: CNTG ) said it launched a next generation sequencing (NGS)-based assay called NEW CentoGenome. NEW CentoGenome is a commercially available Whole Genome Sequencing (WGS) test on the market for rare and neurodegenerative disorders ...

Aims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosis Combines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline with the CENTOGENE Biodatabank, consisting of approximately 700,000 patients representing over...

2023-04-11 07:07:49 ET Centogene ( NASDAQ: CNTG ) said it extended its collaboration with Takeda Pharmaceutical ( NYSE: TAK ) to diagnose patients with Lysosomal Storage Disorders (LSDs). Under the renewed one-year agreement, Centogene will continue to provide ...

The global market access and expansion partnership, initially established in 2015, aims to provide an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) Diagnosis plays a critical role in guiding patients towards appropriate and readily available therapies ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the appointment of Ian Rentsch as Chief Commercial Officer and Gen...